ArticleAbdominal radiology (New York)2026
Imaging biomarkers of liver hypertrophy after portal vein embolization in patients with liver tumors: cholestasis, arterial hyperperfusion, and splenic response.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo identify imaging and clinical factors associated with future liver remnant (FLR) hypertrophy after portal vein embolization (PVE) prior to major hepatectomy. MATERIALS AND
methodsThis retrospective single-center study included 98 patients (mean age 61 ± 14 years, 56 female) with benign or malignant liver tumors who underwent PVE between 2019 and 2024 before planned major liver resection. 10 patients also received liver venous deprivation (LVD). FLR volumes were measured on cross-sectional imaging before and after PVE. Embolic agent, cholestasis, arterial perfusion patterns, signal intensities in MRI, spleen volume, and venous diameters were assessed.
resultsMean FLR growth was 35.6 ± 22.2% (628.9 ± 256.2 to 979.6 ± 313.8 ml (p < 0.001)). Patients undergoing combined LVD demonstrated significantly greater FLR hypertrophy (mean FLR growth 61.3 ± 23.1%, 422 ± 97 ml; p < 0.001) compared with PVE alone. Arterial hyperperfusion of the embolized liver lobe was found to be associated with increased FLR growth (p = 0.036). Isolated cholestasis confined to the embolized lobe was also associated with greater FLR hypertrophy (p = 0.038), whereas cholestasis involving the FLR was associated with impaired growth (p = 0.042). No significant difference in FLR hypertrophy was observed regarding the used embolic agent (p = 0.11). Splenic volume increased significantly following PVE (311.9 ± 146.5 mL after PVE vs. 271.3 ± 118.5 mL prior to PVE, p < 0.001).
conclusionImaging features such as arterial hyperperfusion and cholestasis of the embolized liver lobe, and postinterventional splenic enlargement are associated with larger FLR-growth. These findings may provide valuable early indicators of regenerative response and could help refine patient selection for PVE and hepatectomy, warranting further prospective evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.